Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Status
Active
Cancer Type
Unknown Primary
Trial Phase
Phase I
Eligibility
18 and over, Male and Female
Study Type
Treatment
NCD ID
NCT02715284
Protocol IDs
4010-01-001 (primary)
NCI-2016-01910
Study Sponsor
Tesaro Inc

Summary

This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti

programmed death receptor 1 (anti-PD-1) antibody TSR-042 in patients with advanced solid

tumors who have limited available treatment options. The study will be conducted in 2 parts:

dose escalation and cohort expansion.

Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.